FORVIA: IMPLEMENTATION OF THE SHARE BUYBACK PROGRAM APPROVED BY THE SHAREHOLDERS' MEETING HELD ON MAY 30, 2024
NANTERRE (FRANCE)APRIL 18, 2025
IMPLEMENTATION OF THE SHARE BUYBACK PROGRAM APPROVED BY THE SHAREHOLDERS' MEETING HELD ON MAY 30, 2024
As part of the share buy-back program authorized by the Shareholders' Meeting held May 30, 2024, FORVIA signed with an investment services provider a mandate for the acquisition of a maximum of 300,000 FORVIA shares during a period starting from April 23, 2025 until May 27, 2025 at the latest.
Shares buybacks are intended to hedge FORVIA's commitments under performance share plans or any long-term incentive plan to the benefit of employees and corporate officers of the FORVIA group.
The description of the share buyback program (details of which are on page 470 & s. of the 2023 FORVIA Universal Registration Document filed with the Autorité des marchés financiers on February 27, 2024) and the text of the 19th resolution of the Shareholders' Meeting referred to above are available on the website of the Company, www.forvia.com, respectively under the heading "Investors / Regulated Information" and 'Investors / Shareholders / Shareholders meetings' sections.
PRESS
ANALYSTS/INVESTORS
Christophe MALBRANQUEGroup Influence Director+33 (0) 6 21 96 23 53christophe.malbranque@forvia.com
Adeline MICKELERHead of Investor Relations+33 (0) 1 72 36 75 70adeline.mickeler@forvia.com
Sébastien LEROYDeputy head of Investor Relations+33 (0) 1 72 36 78 74sebastien.leroy@forvia.com
About FORVIA, whose mission is: 'We pioneer technology for mobility experiences that matter to people'.
FORVIA, a global automotive technology supplier, comprises the complementary technology and industrial strengths of Faurecia and HELLA. With around 250 industrial sites and 78 R&D centers, over 150,000 people, including more than 15,000 R&D engineers across 40+ countries, FORVIA provides a unique and comprehensive approach to the automotive challenges of today and tomorrow. Composed of 6 business groups and a strong IP portfolio of over 13,000 patents, FORVIA is focused on becoming the preferred innovation and integration partner for OEMs worldwide. In 2024, the Group achieved a consolidated revenue of 27 billion euros. FORVIA SE is listed on the Euronext Paris market under the FRVIA mnemonic code and is a component of the CAC SBT 1.5° index. FORVIA aims to be a change maker committed to foreseeing and making the mobility transformation happen. www.forvia.com
Attachment
2025 04 18 SHARE BUYBACK PROGRAM
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 hours ago
- Yahoo
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 30, 2025
Information regarding the total number of voting rights and total number of shares of the Company as of May 30, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 05/30/2025 136,973,697 Total gross of voting rights: 136,973,697 Total net* of voting rights: 136,738,528 * Net total = total number of voting rights attached to shares – shares without voting rights Attachment PDF VersionError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document
Châtillon, France, June 03, 2025 DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the 'Company'), today announced today the filing of an addendum to the 2024 Universal Registration Document (the 'Addendum') with the French market authority, 'Autorité des Marchés Financiers' ('AMF'). This Addendum provides an update to the Board of Directors' Corporate Governance Report to account for the exceptional compensation granted to the Chief Executive Officer by the Board of Directors during its meeting on April 30, 2025. The payment of this exceptional compensation remains subject to the approval of the Annual Combined General Meeting to be held on June 11, 2025. The URD and the addendum are available on the Company's website at : and on the AMF website: copies of both documents are available, free of charge, at the Company's headquarters and registered office located at 107, avenue de la République, 92320 Châtillon, France. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary technology platform, Viaskin, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit and engage with us on X (formerly Twitter) and LinkedIn. Investor Contact Katie MatthewsDBV Media ContactAngela MarcucciDBV Attachment PDF VersionError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document
Châtillon, France, June 03, 2025 DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the 'Company'), today announced today the filing of an addendum to the 2024 Universal Registration Document (the 'Addendum') with the French market authority, 'Autorité des Marchés Financiers' ('AMF'). This Addendum provides an update to the Board of Directors' Corporate Governance Report to account for the exceptional compensation granted to the Chief Executive Officer by the Board of Directors during its meeting on April 30, 2025. The payment of this exceptional compensation remains subject to the approval of the Annual Combined General Meeting to be held on June 11, 2025. The URD and the addendum are available on the Company's website at : and on the AMF website: copies of both documents are available, free of charge, at the Company's headquarters and registered office located at 107, avenue de la République, 92320 Châtillon, France. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary technology platform, Viaskin, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit and engage with us on X (formerly Twitter) and LinkedIn. Investor Contact Katie MatthewsDBV Media ContactAngela MarcucciDBV Attachment PDF VersionError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data